108,984 Shares in Arrowhead Pharmaceuticals Inc (ARWR) Acquired by Seven Eight Capital LP

Seven Eight Capital LP bought a new stake in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 108,984 shares of the biotechnology company’s stock, valued at approximately $2,089,000.

A number of other large investors have also recently modified their holdings of the stock. First Allied Advisory Services Inc. lifted its stake in Arrowhead Pharmaceuticals by 5.5% in the 2nd quarter. First Allied Advisory Services Inc. now owns 64,350 shares of the biotechnology company’s stock valued at $875,000 after purchasing an additional 3,350 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Arrowhead Pharmaceuticals by 28.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 25,200 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 5,650 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at about $100,000. Great West Life Assurance Co. Can acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at about $106,000. Finally, United Services Automobile Association lifted its stake in Arrowhead Pharmaceuticals by 69.6% in the 2nd quarter. United Services Automobile Association now owns 19,043 shares of the biotechnology company’s stock valued at $259,000 after purchasing an additional 7,816 shares during the last quarter. Institutional investors and hedge funds own 59.37% of the company’s stock.

In other news, CFO Kenneth Allen Myszkowski sold 45,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $19.34, for a total transaction of $870,300.00. Following the transaction, the chief financial officer now directly owns 335,815 shares of the company’s stock, valued at $6,494,662.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $14.45, for a total transaction of $1,445,000.00. Following the transaction, the chief executive officer now directly owns 1,868,789 shares in the company, valued at $27,004,001.05. The disclosure for this sale can be found here. Insiders have sold 309,834 shares of company stock valued at $4,697,151 over the last 90 days. Company insiders own 4.60% of the company’s stock.

Several equities research analysts recently issued reports on ARWR shares. Jefferies Financial Group raised their target price on shares of Arrowhead Pharmaceuticals to $24.00 and gave the company a “buy” rating in a research note on Friday, September 14th. Cantor Fitzgerald initiated coverage on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, August 1st. They issued a “buy” rating and a $13.00 target price for the company. B. Riley upgraded shares of Arrowhead Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $18.00 to $19.00 in a research report on Thursday, September 6th. Chardan Capital raised their price objective on shares of Arrowhead Pharmaceuticals from $17.50 to $24.50 and gave the stock a “buy” rating in a research report on Thursday, September 6th. Finally, BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $21.45.

Shares of ARWR stock opened at $12.98 on Tuesday. The company has a current ratio of 8.69, a quick ratio of 8.69 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals Inc has a 12-month low of $3.01 and a 12-month high of $22.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $0.62 million. Arrowhead Pharmaceuticals had a negative net margin of 400.13% and a negative return on equity of 59.39%. Equities research analysts expect that Arrowhead Pharmaceuticals Inc will post -0.65 EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply